Tea Oil (Camellia Oil) For Injection BP EP USP Pharma Grade: Product Description and Properties

What Is Tea Oil (Camellia Oil) For Injection?

Tea Oil, known in the pharmaceutical world as Camellia Oil, comes from the seeds of the Camellia oleifera plant and appears as a clear, pale yellow liquid. In pharma-grade quality, especially those meeting BP, EP, and USP, the oil fulfills strict safety and purity requirements. Professionals often use this oil for its gentle nature and as a carrier for some injectables. The attention it gets in the pharmaceutical industry isn’t by accident—it’s earned by meeting chemical and physical standards you don’t get with kitchen-grade camellia oils or unrefined seed extracts. Its raw material qualities go through rigorous analysis from seed selection to the finished, filtered oil, targeting contaminant control and optimal refinement.

Physical and Chemical Properties

Pharma-grade Tea Oil (Camellia Oil) arrives as a clear, transparent liquid at room temperature. No visible impurities, no odor if quality tests pass the bar. The density ranges between 0.910 and 0.920 g/mL at 20°C, matching essential parameters set by pharmacopoeial specifications. It doesn’t come in flakes, powder, solid, pearls, or crystal—the grade made for injection stays strictly liquid, sidestepping bottlenecks in solubility and stability for injectable formulations. The molecular structure reflects the camellia oil native triglyceride backbone, composed mainly of oleic acid chains, supporting a balanced profile between stability and compatibility.

Molecular Formula and Structure

The molecular formula, often represented as C57H104O6, defines the triglyceride backbone—three fatty acids connected to a glycerol moiety. Each molecule packs high proportions of monounsaturated fatty acids (chiefly oleic acid, sometimes over 80%), which makes it less prone to oxidation than other seed oils. This structure supports consistent performance in injectable products and fits the chemical demands set by international pharmacopoeia guidelines.

Product Specifications and Quality Standards

Products labeled BP, EP, or USP pharma grade tea oil follow fixed routes for sourcing, pressing, refining, and filtration to rid the oil of harmful impurities, proteins, and moisture. Every batch needs verification for specific gravity, free fatty acid content, peroxide value, saponification value, and solubility in pharmaceutical carriers. The pharma grades require documentation of residue on ignition and acid value, regularly checked in audits and quality control measures. Specifications for water content fall under tight control (<0.1%), since any moisture in injectable grade oils can trigger complications—think microbial growth or stability drop-off.

HS Code and Global Trade Information

On global ledgers, Tea Oil for pharma-grade injection applications typically clears customs under HS Code 151590. Customers expect clear documentation for this code on customs forms and certificates of analysis. This streamlines trade and satisfies border requirements. For pharmaceutical chains seeking ethical and traceable raw materials, correct HS Codes reduce compliance risks.

Material Properties, Density, and Safety Profile

Tea Oil as injection-grade raw material stands out by its physicochemical integrity. Its specific density (between 0.910–0.920 g/mL) secures performance in blends and solutions. The fatty acid profile resists rancidity, reducing the likelihood of breakdown, and minimizing hazardous byproduct formation. Safety data shows low acute toxicity, with no recognized harmful byproducts when the oil is handled correctly and purified to pharma guidelines. Safe for parenteral use when standards meet regulatory levels, though production environments must strictly avoid contamination.

Use and Quality in the Pharmaceutical Field

The demand for Camellia Oil in medical-grade usage follows growing interest in plant-based alternatives to traditional oils like soybean and safflower oil used in injections. Clinical researchers link its high monounsaturated fat to reduced inflammatory markers, while emulsion stability finds favor in parenteral formulas. Teams in manufacturing environments trust this oil because it rarely triggers adverse reactions if extracted and purified right. As an excipient, it works in intravenous fat emulsions, slow-release drugs, and pre-filled vials. Real-world experiences in sterile facilities show that tight control in processing, from deacidification to deodorization, gates risks—critical when patient safety rides on every lot released.

Hazard and Harmful Material Assessment

Hazard assessments for this pharma-grade raw material underline typical threats: improper storage can spur peroxides, heat can accelerate breakdown, and residual proteins or water can prompt reactions in patients. Manufacturers mitigate these risks with closed, monitored facilities and comprehensive batch testing. Regulatory frameworks enforce maximum residue limits, not just for heavy metals or solvents, but also for toxins and pesticide residues. Reputable suppliers maintain detailed safety data sheets and batch traceability for every container, which arms hospital pharmacists and regulatory inspectors with ammunition against substandard supplies.

Potential Solutions and Industry Concerns

Addressing challenges surrounding global demand, authentic sourcing, and continuous quality improvement matters. Industry players swap best practices in filtration, purification, and rapid batch analytics to shrink lead times and catch contamination early. Integrating molecular fingerprinting or blockchain tracking could push traceability. For clinical risk, standardized operator training and routine revalidation of analytical infrastructure help reinforce patient safety across the value chain, making sure no short-cuts sneak into the process. Environmental impacts spark conversation—sustainable sourcing and responsible waste disposal, particularly of spent seeds and extraction solvents, are steps in responsible production not to neglect.